Electrophysiology of sipatrigine: A lamotrigine derivative exhibiting neuroprotective effects

Experimental Neurology

Volumn 162, Issue 1, 2000, Pages 171-179

  Calabresi, Paolo ^a,b   Stefani, Alessandro ^a   Marfia, Girolama A ^a   Hainsworth, Atticus H ^c   Centonze, Diego ^a   Saulle, Emilia ^a   Spadoni, Francesca ^a   Leach, Michael J ^d   Giacomini, Patrizia ^e   Bernardi, Giorgio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c DE MONTFORT UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF GREENWICH   (United Kingdom)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Antiepileptic drugs; Neuroprotective drugs; Sodium currents; Stroke; Synaptic potentials

Indexed keywords

LAMOTRIGINE; SIPATRIGINE; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; ELECTROPHYSIOLOGY; EXCITATORY POSTSYNAPTIC POTENTIAL; MALE; MEMBRANE POTENTIAL; NERVE CELL; NEUROPROTECTION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; RAT; SODIUM CURRENT; STROKE; SYNAPTIC POTENTIAL;

EID: 17344391838     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7285     Document Type: Article

References (46)

1. Atluri P. P., Regehr W. G. Determinants of the time course of facilitation at the granule cell to Purkinje cell synapse. J. Neurosci. 16:1996;5661-5671.
2. Calabresi P., Centonze D., Marfia G. A., Pisani A., Bernardi G. An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons. Br. J. Pharmacol. 126:1999;689-696.
3. Calabresi P., Centonze D., Pisani A., Sancesario G., Gubellini P., Marfia G. A., Bernardi G. Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease. Ann. Neurol. 43:1998;586-597.
4. Calabresi P., De Murtas M., Stefani A., Pisani A., Sancesario G., Mercuri N. B., Bernardi G. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. I. Modulation of corticostriatal synaptic transmission. Epilepsia. 36:1995;990-996.
5. Calabresi P., Magarinos Ascone C., Centonze D., Pisani A., Sancesario G., D'Angelo V., Bernardi G. Opposite membrane potential changes induced by glucose deprivation in striatal spiny neurons and in large aspiny interneurons. J. Neurosci. 17:1997;1940-1949.
6. Calabresi P., Mercuri N. B., Bernardi G. Synaptic and intrinsic control of membrane excitability of neostriatal neurons. II. An in vitro analysis. J. Neurophysiol. 63:1990;663-675.
7. Calabresi P., Mercuri N. B., Stanzione P., Stefani A., Bernardi G. Intracellular studies on the dopamine-induced firing inhibition of neostriatal neurons in vitro: Evidence for D1 receptor involvement. Neuroscience. 20:1987;145-157.
8. Calabresi P., Pisani A., Mercuri N. B., Bernardi G. Post-receptor mechanisms underlying striatal long-term depression. J. Neurosci. 14:1994;4871-4881.
9. Calabresi P., Pisani A., Mercuri N. B., Bernardi G. The corticostriatal projection: From synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci. 19:1996;19-24.
10. Centonze D., Calabresi P., Pisani A., Marinelli S., Marfia G. A., Bernardi G. Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology. 37:1998;1063-1070.
11. Cepeda C., Walsh J. P., Peacock W., Buckwald N. A., Levine M. S. Neurophysiological, pharmacological and morphological properties of human caudate neurons recorded in vitro. Neuroscience. 59:1994;89-103.
12. Chen J., Graham S. H., Simon R. P. A comparison of the effects of a sodium channel blocker and an NMDA antagonist upon extracellular glutamate in rat focal cerebral ischemia. Brain Res. 699:1995;121-124.
13. Cheung H., Kamp D., Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res. 13:1992;107-112.
14. Dolphin A. C. Voltage-dependent calcium channels and their modulation by neurotransmitters and G proteins. Exp. Physiol. 80:1995;1-36.
15. 2+ channels in mammalian central neurons. Trends Neurosci. 18:1995;89-98.
16. Edwards M. D., Leach M. J., Lees G. Molecular mode of action of the neuroprotective agent BW619C89. Anesthesiology. 81:1994;A857.
17. Graham S. H., Chen J., Lan J., Leach M. J., Simon R. P. Neuroprotective effects of a use-dependent blocker of voltage-dependent sodium channels, BW619C89, in rat middle cerebral artery occlusion. J. Pharmacol. Exp. Ther. 269:1994;854-859.
18. Green A. R., Cross A. J. Neuroprotective agents and cerebral ischaemia. International Review of Neurobiology. 1997;Academic Press, London.
19. Greene J. G., Greenamyre J. T. Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol. 48:1996;613-634.
20. Hunter A. J. Calcium antagonists: Their role in neuroprotection. Green A. R., Cross A. J. Neuroprotective Agents and Cerebral Ischaemia. 1997;95-108 Academic Press, London.
21. Jiang Z.-C., North R. A. Membrane properties and synaptic responses of rat striatal neurones in vitro. J. Physiol. (London). 443:1991;533-553.
22. Kawaguchi K., Graham S. H. Neuroprotective effects of the glutamate release inhibitor 619C89 in temporary middle cerebral artery occlusion. Brain Res. 749:1997;131-134.
23. Kita T., Kita H., Kitai S. T. Passive electrical membrane properties of rat neostriatal neurons in an in vitro slice preparation. Brain Res. 300:1984;129-139.
24. Krieglstein J. Mechanisms of neuroprotective drug actions. Clin. Neurosci. 4:1997;184-193.
25. Kristian T., Siesjo B. K. Calcium in ischemic cell death. Stroke. 29:1998;705-718.
26. Leach M. J., Lees G., Riddall D. R. Lamotrigine: Mechanisms of action. Levy R. H., Mattson R. H., Meldrum B. S. Antiepileptic Drugs. 1995;Raven Press, New York.
27. Leach M. J., Swan J. H., Eisenthal D., Dopson M., Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischaemic damage. Stroke. 24:1993;1063-1067.
28. Lees G., Leach M. J. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res. 612:1993;190-199.
29. Manabe T., Wyllie D. J., Perkel D. J., Nicoll R. A. Modulation of synaptic transmission and long-term potentiation: Effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J. Neurophysiol. 70:1993;1451-1459.
30. 2+ channels by the neuroprotective agent BW619C89. Neuropharmacology. 36:1997;1795-1798.
31. Meldrum B. S., Smith S. E., Lekieffre D., Chapman A. G., Graham J. L., Pearce P. C. Sodium-channel blockade and glutamate release: The mechanism of cerebroprotection by lamotrigine, BW1003C87 and BW619C89. Krieglstein J., Oberpichler-Schwenk H. Pharmacology of Cerebral Ischaemia. 1994;203-209 Wissenschiftlicke-Verlagagesellshaft, Stuttgart.
32. Muir K. W., Lees K. R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 26:1995;503-513.
33. Muir K. W., Lees K. R., Hamilton S. J., George C. F., Hobbiger S. F., Lunnon M. W. A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke. Ann. N. Y. Acad. Sci. 765:1995;328-329.
34. Olivera B. M., Miljanich G. P., Ramachandran J., Adams M. E. Calcium channel diversity and neurotransmitter release: The omega-conotoxins and omega-agatoxins. Annu. Rev. Biochem. 63:1994;823-867.
35. Schulz P. E., Cook E. P., Johnston D. Changes in paired-pulse facilitation suggest presynaptic involvement in long-term potentiation. J. Neurosci. 14:1994;5325-5337.
36. Smith S. E., Hodges H., Sowinski P., Man C.-M., Leach M. J., Sinden J. D., Gray J. A., Meldrum B. S. Long-term beneficial effects of BW619C89 on neurological deficit and brain damage after middle cerebral artery occlusion in the rat. Neuroscience. 77:1997;1123-1135.
37. Stefani A., Hainsworth A. H., Spadoni F., Bernardi G. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89. Br. J. Pharmacol. 125:1998;1058-1064.
38. 2+ currents in cortical neurons: Functional implications. Eur. J. Pharmacol. 307:1996;113-116.
39. + channels, glutamate release and NMDA receptors mediates delayed neurodegeneration through nitric oxide formation. J. Neurosci. 16:1996;5004-5013.
40. Szatkowski M., Attwell D. Triggering and execution of neuronal death in brain ischaemia: Two phases of glutamate release by different mechanisms. Trends Neurosci. 17:1994;359-365.
41. Tsuchida E., Harms J. F., Woodward J. J., Bullock R. A use-dependent sodium channel antagonist, 619C89, in reduction of ischemic brain damage and glutamate release after acute subdural hematoma in the rat. J. Neurosurg. 85:1996;104-111.
42. + channels: A rational and effective strategy against ischemic brain damage. Pharmacol. Rev. 48:1996;21-67.
43. Wang S.-J., Huang C.-C., Hsu K.-S., Tsai J.-J., Gean P.-W. Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Synapse. 24:1996;248-255.
44. Wheeler D. B., Randall A. D., Tsien R. W. Changes in action potential duration alter reliance of excitatory synaptic transmission on multiple types of Ca channels in rat hippocampus. J. Neurosci. 16:1996;2226-2237.
45. Xie X. M., Garthwaite J. State-dependent inhibition of Na currents by the neuroprotective agent 619C89 in rat hippocampal neurons and in a mammalian cell line expressing rat brain type IIA Na channels. Neuroscience. 73:1996;951-962.
46. + channels in rat hippocampal neurones. Eur. J. Physiol. 430:1995;437-446.